Needham Downgrades Apellis Pharmaceuticals (APLS) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
William Blair Downgrades Apellis Pharmaceuticals (APLS) to Market Perform
March 31, 2026 11:55 AM EDTWilliam Blair analyst Lachlan Hanbury-Brown downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Apellis Pharmaceuticals click here. For more ratings news on Apellis Pharmaceuticals click here.
Shares of Apellis Pharmaceuticals closed at $17.09 yesterday.
... More


